BioMarin CCO Jeffrey Ajer to step down effective July 1, 2024

BIOMARIN PHARMACEUTICAL INC

Jeffrey Ajer, EVP and Chief Commercial Officer, will depart on July 1, 2024.
No successor named; compensation unchanged until departure date.
Separation treated as without-cause termination; Ajer eligible for severance per employment agreement.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Jeffrey Ajer

Executive Vice President and Chief Commercial Officer

BMRN · BIOMARIN PHARMACEUTICAL INC

Effective: 2024-07-01
Filed: January 11, 2024, 6:59 PM ET

On January 11, 2024, BioMarin Pharmaceutical Inc. (“BioMarin” or the “Company”) announced that Mr. Jeffrey Ajer would step down as the Company’s Executive Vice President and Chief Commercial Officer, effective July 1, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jeffrey Ajer departed as Executive Vice President and Chief Commercial Officer at BIOMARIN PHARMACEUTICAL INC.

Action: step down
Role: Executive Vice President and Chief Commercial Officer

Exact text from the filing

On January 11, 2024, BioMarin Pharmaceutical Inc. (“BioMarin” or the “Company”) announced that Mr. Jeffrey Ajer would step down as the Company’s Executive Vice President and Chief Commercial Officer, effective July 1, 2024.

View on SEC.gov

BIOMARIN PHARMACEUTICAL INC filing history →

Source: SEC EDGAR

accession 0001193125-24-006599

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.